The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Large Volume Wearable Injectors (2nd Edition)

  • Lowest Price Guaranteed From USD 1,899

  • Published
    September 2014

  • Pages
    242

  • View Count
    4366

Example Insights

An updated edition is available at the following link 

View 4th edition

  1. In total, over 15 large volume wearable drug delivery devices (including variants) currently under development have been identified during our research.
  2. Approximately 53% of these devices operate electronically. Other modes of operation include mechanical, hydrogel and hydraulic. Many of these injectors have additional features such as an audio / visual panel making their usage very easy for the end users.
  3. The range of volume these devices can cater to is as high as 30 ml. The first commercial launch is anticipated to take place in 2015/2016. In our research, we have profiled five drugs which are currently undergoing trials for delivery via large volume injectors.
  4. Pharma companies also have many undisclosed research programs.We have identified about 30 biologics which are likely to be immediate targets for preparation of subcutaneous formulation and delivery via large volume wearable injectors. In addition to these highly likely candidates, there are more than 100 other drug-disease combinations which are expected to draw interest in the short-mid term.
  5. The manufacturer’s landscape is still evolving. In addition the established firms such as Becton Dickinson and West Pharma, many start-ups including Unilife, Sensile Medical, SteadyMed Therapeutics and Enable Injections are heading towards the pole position
  6. The growth in biologics will be one of the key drivers for the emergence of large volume wearable injectors. Around 50% of the top 100 selling drugs are expected to be biologics by 2016; biologics are estimated to contribute 27% of the total drugs market by 2020.
  7. Other key reasons for the growth of bolus injectors include their potential to act as life cycle management tool, increasing trend towards drug self-administration and the overall drive towards cheaper healthcare costs.

Overview

The injectable drug delivery market holds significant potential for the future. From the conventional syringes with vials and painful needles to the modern-day pre-filled syringes, pen-injectors, needle free injectors and auto-injectors, the market has come a long way. The rising prevalence of chronic diseases is one of the key factors driving the companies to develop systems that allow patients to self-administer drugs. Taking the concept of self-injectors to a new stratum, ‘Large volume Wearable Injectors’ have surfaced recently. Also known as bolus injectors and non-insulin patch pumps, these devices not only offer a range of benefits to the end users but also provide a number of additional benefits to other stakeholders in the industry.

One of the main drivers for the perceived growth of these injectors is the large number of biologics currently under development. A majority of these molecules are highly viscous and are required to be delivered in volumes of greater than 1 ml. The absence of devices which can safely administer these drugs is currently a big unmet need in the market. However, the early signs are encouraging. Despite the uncertainties related to the device development and approval, many companies are investing time, money and resources to develop novel devices. Some customized drug-device combinations are currently being developed for specific drugs such as Herceptin, AMG-145 and Furosemide. In addition, pharma companies have many undisclosed programs which are likely to provide the necessary growth impetus in the near future.

This development is being led jointly by established firms such as Becton Dickinson, West Pharmaceuticals and emerging players such as Unilife, SteadyMed Therapeutics, Ratio Drug Delivery, Sensile Medical, Enable Injections and scPharmaceuticals. It is widely anticipated that, once ready, such devices which will allow self-administration of high viscosity, large volume biologics and be readily adopted in the industry.

 

Scope of the Report

The ‘Large Volume Wearable Injectors’ market report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Starting with the basic introduction to these injectors, the report lays emphasis on the current unmet needs of the market. As all the large volume wearable injectors are currently only available for investigational use, the investment being done in this area is geared towards tapping the significant future potential of this market. In fact, one of the primary objectives of this report is to estimate the size of this future promise offered by such injectors.

A large number of biologics are currently under development and a majority of these molecules are highly viscous and require to be delivered in volumes of greater than 1 ml. It is widely anticipated that devices which will allow self-administration of these molecules will be readily adopted by all stakeholders in the industry. For the purposes of our analysis, we followed a top-down approach to estimate the size of this market. This included:

  • Conducting an extensive research to identify high viscosity and large volume biologics which are either currently under development or are already marketed.
  • Based on the standard dosage regime and the likely injection frequency, shortlisting the highly likely candidates for delivery via bolus injectors.
  • For these molecules under development, estimating the likely timeline by when they will be ready for subcutaneous administration.
  • Estimating the proportion of these molecules which will be available for subcutaneous delivery via large volume wearable injectors for around 14 disease classes.
  • Estimating the sales potential (both in terms of value and volume) of these injectors for each drug-disease combination over the next ten years.

Where possible, we have added robustness to our forecasting model by conducting extensive primary research interviews with senior stakeholders in the industry. Owing to the uncertain nature of the market, we have provided three scenarios for our market forecast. The conservative, base and optimistic scenarios are considered for the forecasting of each of the analysed drug-disease combinations and represent three different tracks of industry evolution.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of the bolus injectors market.

Chapter 3  provides a general introduction to the market and the historical evolution of self-administration injection devices. The chapter also talks about needlestick injuries and the growing preference towards safe and easy-to-use devices.

Chapter 4  provides a detailed overview on wearable injectors and the various unmet needs which are fuelling the rise of these injectors. It not only provides a detailed introduction to large volume wearable injectors but also highlights their key features and categorises the various large volume wearable injectors (currently under development) by mode of operation, device usage and volume.

Chapter 5  highlights the various molecules which are likely to form the target market of large volume wearable injectors. It also looks at the likely growth of biologics market over the next ten years; this is expected to be a significant driver for the large volume wearable injectors which are likely to become the preferred device for delivery of high viscous, large volume biologics.

Chapter 6  provides detailed case studies on five drugs being targeted to deliver through bolus injectors/patch pumps.

Chapter 7  includes detailed profiles of various large volume wearable injectors, their applications, usage mechanism and current state of development.

Chapter 8  looks at the future state of large volume wearable injectors market till 2025. It highlights the leading disease classes which will drive this growth and the relative market size of large volume wearable injectors within each disease class, both in terms of the number of units and the value of the market.

Chapter 9  provides the SWOT analysis of large volume wearable injectors market giving strategic insights to the major factors that are likely to contribute to the growth while also highlighting the weakness and threats that can negatively impact the growth.

Chapter 10  includes profiles of the key companies in the large volume wearable injectors market. Each company profile includes information such as financial performance, marketed / pipeline products, recent developments and future growth plans.

Chapter 11  is a collection of transcripts of some of the interviews which were conducted while preparing this report.

Chapter 12  summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in the previous chapters.

Chapter 13  is an appendix, which provides tabulated data and numbers for all the figures presented in the report.

Chapter 14  is an appendix, which provides a list of companies and organisations mentioned in this report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Conventional Needle and Syringe Delivery
3.3. Self-administration of Drugs
3.3.1. Rising Burden of Chronic Diseases
3.3.2. Systems Available for Self-administration
3.4. Needlestick Injuries
3.4.1. Incidence and Cost Burden
3.4.2. Government Legislation for Needlestick Injury Prevention
3.5. Safety Options in Self Injectors
 
4. OVERVIEW AND MARKET BACKGROUND
4.1. Chapter Overview
4.2. What Are Wearable Injectors?
4.3. The Need for Wearable Injectors
4.3.1. Advancements in Drug Classes
4.3.2. Need for Better Patient Compliance
4.4. Types of Wearable Injectors
4.4.1. Insulin Pumps with Infusion Sets
4.4.2. Insulin Patch Pumps
4.4.3. Transdermal Patch
4.4.4. Bolus Injectors
4.5. Our Scope of Large Volume Wearable Injectors
4.6. Components of a Large Volume Wearable Injector
4.7. Classification of Large Volume Wearable Injectors
4.7.1. Mechanism Based Classification
4.7.2. Usage Based Classification
4.7.3. Drug Delivery Based Classification
4.7.4. Volume Based Classification
4.8. Large Volume Wearable Injectors Under Development
4.8.1. Distribution by Mode of Operation
4.8.2. Distribution by Device Usage
4.8.3. Distribution by Volume
4.9. Factors Driving the Large Volume Wearable Injectors Market
4.9.1. Growth of Biologics and Biosimilars
4.9.2. Life Cycle Management Activities Driving Demand for Alternative Delivery Systems
4.9.3. Need for Brand Differentiation
4.9.4. Drive towards Cheaper Healthcare Costs
4.9.5. Convenient Drug Reconstitution
4.9.6. Interest from Multinational Pharmaceutical Companies
 
5. TARGET DRUGS FOR LARGE VOLUME WEARABLE INJECTORS
5.1. Chapter Overview
5.2. Biologics Market
5.2.1. Biologics Market Forecast, 2014-2020
5.2.2. Biologics Market Trends
5.2.3. Biologics: Likely Targets for Large Volume Wearable Injectors
 
6. CASE STUDIES
6.1. Chapter Overview
6.2. Case Study: Herceptin (Genentech/Roche)
6.2.1. Background and History of Development
6.2.2. Indications and Dosage Forms
6.2.3. Target Population
6.2.4. Sales, 1999 – 2013
6.2.5. Launch of Subcutaneous Formulation
6.2.6. ENHANZE™: The Technology Behind Subcutaneous Formulation of Herceptin (Halozyme Therapeutics)
6.2.7. Advantages of Subcutaneous Form Over Intravenous
6.2.8. Herceptin Likely to be the First Biologic to be Launched in Bolus Injector
 
6.3. Case Study: Furosemide and Cephalosporin (scPharmaceuticals)
6.3.1. Furosemide
6.3.1.1. Background and History of Development
6.3.1.2. Dosage Forms
6.3.1.3. Sales 2010-2012
6.3.1.4. Advantages of Subcutaneous Form Over Intravenous delivery of furosemide
6.3.2. Cephalosporin
6.3.2.1. Background and History of Development
6.3.2.2. Dosage Forms
6.3.3. scPharmaceuticals and Sensile Medical Strategic Partnership
6.3.4. The Technology Behind Subcutaneous administration of furosemide and cephalosporin
 
6.4. Case Study: Evolocumab / AMG 145 (Amgen)
6.4.1. History of Development
6.4.2. Current Status
6.4.3. Indications and Dosage Forms
6.4.4. Target Population
6.4.5. Future Plans
 
6.5. Case Study: ND0612L (NeuroDerm)
6.5.1. Background and History of Development
6.5.2. Dosage Forms
6.5.3. Target Population
6.5.4. Sales
6.5.5. Levodopa/Carbidopa Subcutaneous Administration through a Patch Pump
 
7. PRODUCT PROFILES
7.1. Chapter Overview
7.2. MyDose (Roche)
7.2.1. Introduction
7.2.2. Product Description
7.2.3. Usage / Mechanism
7.2.4. Advantages
7.2.5. Manufacturing of MyDose
7.2.6. Current Status
 
7.3. BD Libertas™ Patch Injector (BD MEDICAL, A Segment of Becton Dickinson and Company)
7.3.1. Introduction
7.3.2. Product Description
7.3.3. Usage / Mechanism
7.3.4. Advantages
7.3.5. Current Status
 
7.4. SmartDose (West Pharmaceutical Services, Inc.)
7.4.1. Introduction
7.4.2. Product Description
7.4.3. Usage / Mechanism
7.4.4. Advantages
7.4.5. Current Status
 
7.5. Precision-Therapy™ and Flex-Therapy™ (Unilife Corporation)
7.5.1. Introduction
7.5.2. Product Description
7.5.3. Usage / Mechanism
7.5.4. Advantages
7.5.5. Current Status
 
7.6. PatchPump (SteadyMed Therapeutics)
7.6.1. Introduction
7.6.2. Product Description
7.6.3. Usage / Mechanism
7.6.4. Advantages
7.6.5. Evaluating the Device for In-House Drugs
7.6.6. Current Status
 
7.7. SenseBolus, SensePatch and SenseTrial (Sensile Medical AG)
7.7.1. Introduction
7.7.2. Product Description
7.7.3. SenseBolus SD
7.7.4. SensePatch (SD and FD)
7.7.5. SenseTrial SD
7.7.6. Usage / Mechanism
7.7.7. Advantages
7.7.8. Current Status
 
7.8. NuPrivo-SC and NuPrivo-CI (Ratio, Inc.)
7.8.1. Introduction
7.8.2. Product Description
7.8.2.1. NuPrivo-SC
7.8.2.2. NuPrivo-CI
7.8.3. Advantages of NuPrivo-SC and NuPrivo-CI
7.8.4. Current Status
 
7.9. Rapid Infuser and V-Go (Valeritas, Inc.)
7.9.1. Introduction
7.9.2. Rapid Infuser
7.9.2.1. Advantages
7.9.3. V-Go
7.9.3.1. Advantages
7.9.4. Current Status
 
7.10. Enable Injector (Enable Injections)
7.10.1. Introduction
7.10.2. Product Description
7.10.3. Usage/Mechanism
7.10.4. Advantages
7.10.5. Current Status
 
7.11. Finesse™ (Calibra Medical)
7.11.1. Introduction
7.11.2. Product Description
7.11.3. Usage/Mechanism
7.11.4. Advantages
7.11.5. Current Status
 
7.12. PaQ™ (CeQur)
7.12.1. Introduction
7.12.2. Product Description
7.12.3. Usage/Mechanism
7.12.4. Advantages
7.12.5. Current Status
 
8. MARKET SIZE AND FORECAST
8.1. Chapter Overview
8.2. Forecast Methodology
8.3. Overall Large Volume Wearable Injectors Market, 2014 – 2025
8.4. Large Volume Wearable Injectors for Cancer and Related Conditions, 2014 – 2025
8.5. Large Volume Wearable Injectors for Autoimmune Diseases, 2014 – 2025
8.6. Large Volume Wearable Injectors for Blood Disorders, 2014 – 2025
8.7. Large Volume Wearable Injectors for Genetic Disorders, 2014 – 2025
8.8. Large Volume Wearable Injectors for Infectious Diseases, 2014 – 2025
8.9. Large Volume Wearable Injectors for Cardiovascular Diseases, 2014 – 2025
8.10. Large Volume Wearable Injectors for Respiratory Disorders, 2014 – 2025
8.11. Large Volume Wearable Injectors for Digestive Disorders, 2014 – 2025
8.12. Large Volume Wearable Injectors for Musculoskeletal Disorders, 2014 – 2025
8.13. Large Volume Wearable Injectors for Diabetes, 2014 – 2025
8.14. Large Volume Wearable Injectors for Eye Conditions, 2014 – 2025
8.15. Large Volume Wearable Injectors for Skin Diseases, 2014 – 2025
8.16. Large Volume Wearable Injectors for Neurologic Disorders, 2014 – 2025
8.17. Large Volume Wearable Injectors for Other Diseases, 2014 – 2025
 
9. SWOT ANALYSIS
9.1. Overview
9.2. Strengths
9.2.1. Greater Flexibility in Dosage Volume and Time of Delivery
9.2.2. Consistent Drug Delivery
9.2.3. Benefits to Other Stakeholders in the Value Chain
9.2.3.1. Benefits to Payers
9.2.3.2. Benefits to Pharmaceutical Companies
 
9.3. Weaknesses
9.3.1. Newness and Uncertainty
9.3.2. Product Stability
9.3.3. Fill/Finish Complexities
 
9.4. Opportunities
9.4.1. Growth of Biologics and Biosimilars
9.4.2. Venture Capital Interest
9.4.3. Life Cycle Management Tool
9.4.4. Paediatric and Geriatric Population
 
9.5. Threats
9.5.1. Alternative Drug Delivery Systems: Autoinjectors and Pen Injectors
9.5.2. Alternative Drug Delivery Systems: Other Wearable Injectors
9.5.3. Case Study: Treprostinil (SteadyMed)
9.5.3.1. Background and History of Development
9.5.3.2. Indications and Dosage Forms
9.5.3.3. Target Population
9.5.3.4. Drug Sales
9.5.3.5. Advantages of Subcutaneous Treprostinil
9.5.3.6. Trevyent™ Patch Pump for subcutaneous administration of Treprostinil
9.5.3.7. Current Status
9.5.4. History of Device Recalls
9.5.5. Reimbursement From Public/Private Healthcare Services
9.5.6. Material Compatibility Issues
 
10. COMPANY PROFILES
10.1. Unilife Corporation
10.1.1. Overview and Background
10.1.2. Financial Performance
10.1.3. Product Portfolio
10.1.3.1. Unifill Platform of Prefilled Syringes
10.1.3.2. EZMix Platform of Dual-Chamber Syringes (Drug Reconstitution Delivery Systems)
10.1.3.3. Auto-Injector Platform
10.1.3.4. Wearable Injector Platform
10.1.3.5. Ocular Delivery Systems
10.1.3.6. Novel Delivery Systems
10.1.4. Recent Developments
10.1.4.1. Partnership with Novartis
10.1.4.2. Partnership with Global Pharmaceutical Company (undisclosed)
10.1.4.3. Partnership with MedImmune
10.1.4.4. Partnership with Hikma
10.1.4.5. Partnership with Sanofi
10.1.4.6. Partnership with Biodel
10.1.5. Future Growth Plans
 
10.2. west Pharmaceutical Services
10.2.1. Overview and Background
10.2.2. Financial Performance
10.2.3. Product Portfolio
10.2.3.1. Marketed Products
10.2.3.2. Pipeline Products
10.2.4. Recent Developments
10.2.4.1. Advancing the Growth of CZ Syringes
10.2.4.2. Looking to Grow in Pharmerging markets (Brazil, China and India)
10.2.4.3. Agreement with Janssen Biotech
10.2.5. Future Growth Plans
 
10.3. BD Medical, A Segment Of Becton, Dickinson and Company
10.3.1. Overview and Background
10.3.2. Financial Performance
10.3.3. Product Portfolio
10.3.3.1. Marketed Products
10.3.3.2. Pipeline Products
10.3.4. Recent Developments
10.3.4.1. Agreement with Biodel
10.3.4.2. Collaboration with World Health Organization (WHO)
10.3.4.3. Launch of BD Sterifill Advance™
10.3.4.4. Entering the Generic Business
10.3.4.5. Acquisition of Cato Software Solution
10.3.4.6. Acquisition of Safety Syringes
10.3.5. Future Growth Plans
 
10.4. Sensile Medical AG
10.4.1. Overview and Background
10.4.2. Product Portfolio
10.4.3. Technology Portfolio
10.4.4. Recent Developments
10.4.5. Future Growth Plans
 
10.5. SteadyMed Therapeutics
10.5.1. Overview and Background
10.5.2. Financial Performance
10.5.3. Product Portfolio
10.5.4. Technology Portfolio
10.5.5. Recent Developments
10.5.6. Future Growth Plans
 
10.6. Ratio, Inc.
10.6.1. Overview and Background
10.6.2. Financial Performance
10.6.3. Product Portfolio
10.6.4. Technology Portfolio
10.6.5. Recent Developments
10.6.6. Future Growth Plans
 
10.7. Valeritas Inc.
10.7.1. Overview and Background
10.7.2. Financial Performance
10.7.3. Product Portfolio
10.7.4. Technology Portfolio
10.7.4.1. h-Patch™
10.7.4.2. Mini-Ject™
10.7.4.3. Micro-Trans™
10.7.5. Recent Developments
 
10.8. Roche Laboratories
10.8.1. Overview and Background
10.8.2. Financial Performance
10.8.3. Product Portfolio
10.8.4. Recent Developments
10.8.4.1. Approval for MabThera
10.8.4.2. Approval for Herceptin
10.8.4.3. ISPE Facility of the Year Award
10.8.5. Future Growth Plans
 
10.9. CeQur
10.10. Calibra Medical
10.11. Batelle
 
11. INTERVIEW TRANSCRIPTS
11.1. Interview 1: Ben Moga, President, Ratio Drug Delivery
11.2. Interview 2: Anonymous, West Pharmaceutical Services
11.3. Interview 3: Michael Hooven, CEO, Enable Injections
11.4. Interview 4: Pieter Muntendam, CEO, scPharmaceuticals
 
12. CONCLUSION
12.1. An Emerging Market Ready to Explode
12.2. Growth of Biologics will be the Single Biggest Driver
12.3. Venture Capital Interest Likely to Stay High
12.4. The Handful of Drug-Device Combination currently in the research pipeline will be the first generation of Large Volume Wearable Injectors
12.5. Concluding Remarks
 
13. APPENDIX 1: Tabulated Data
 
14. APPENDIX 2: List of Companies and Organizations

List of Figures

Figure 3.1 Prevalence of Diabetes, 2013 - By Countries (%)
Figure 4.1 Benefits of Large Volume Wearable Injectors to Stakeholders
Figure 4.2 Large Volume Wearable Injectors: Distribution by Modes of Operation
Figure 4.3 Large Volume Wearable Injectors: Distribution by Device Usage
Figure 4.4 Large Volume Wearable Injectors: Distribution by Volume
Figure 5.1 Total Drugs Market, 2013 - By Nature of Drug (USD Billion, %)
Figure 5.2 Drugs Market Forecast, 2014-2020: Distribution by Biologics and Pharmaceuticals (USD Billion)
Figure 5.3 Biologic Drugs in Development, 2012: Distribution by Type of Molecule (%)
Figure 6.1 HER2 Expression in Breast Cancer Patients (%)
Figure 6.2 Herceptin Sales, 1999 - 2013 (CHF Million)
Figure 6.3 Worldwide Furosemide Sales, 2010-2012 (USD Million)
Figure 6.4 Carbidopa/Levodopa Worldwide Sales, 2010-2012 (USD, Million)
Figure 8.1 Overall Large Volume Wearable Injectors Market (Number of Devices, Millions), 2014 - 2025
Figure 8.2 Overall Large Volume Wearable Injectors Market (USD Million), 2014 - 2025
Figure 8.3 Number of Molecules in Large Volume Wearable Injectors for Cancer and Related Conditions (2014 - 2025)
Figure 8.4 Large Volume Wearable Injectors Market for Cancer and Related Conditions (Number of Devices, Millions), 2014 - 2025
Figure 8.5 Number of Molecules in Large Volume Wearable Injectors for Autoimmune Diseases (2014 - 2025)
Figure 8.6 Large Volume Wearable Injectors Market for Autoimmune Diseases (Number of Devices, Millions), 2014 - 2025
Figure 8.7 Number of Molecules in Large Volume Wearable Injectors for Blood Disorders (2014 - 2025)
Figure 8.8 Large Volume Wearable Injectors Market for Blood Disorders (Number of Devices, Millions), 2014 - 2025
Figure 8.9 Number of Molecules in Large Volume Wearable Injectors for Genetic Disorders (2014 - 2025)
Figure 8.10 Large Volume Wearable Injectors Market for Genetic Disorders (Number of  Devices, Millions), 2014 - 2025
Figure 8.11 Number of Molecules in Large Volume Wearable Injectors for Infectious Diseases (2014 - 2025)
Figure 8.12 Large Volume Wearable Injectors Market for Infectious Diseases (Number of Devices, Millions), 2014 -2025
Figure 8.13 Number of Molecules in Large Volume Wearable Injectors for Cardiovascular Diseases (2014 - 2025)
Figure 8.14 Large Volume Wearable Injectors Market for Cardiovascular Diseases (Number of Devices, Millions), 2014 - 2025
Figure 8.15 Number of Molecules in Large Volume Wearable Injectors for Respiratory Disorders (2014 - 2025)
Figure 8.16 Large Volume Wearable Injectors Market for Respiratory Disorders (Number of Devices, Millions), 2014 - 2025
Figure 8.17 Number of Molecules in Large Volume Wearable Injectors for Digestive Disorders (2014 - 2025)
Figure 8.18 Large Volume Wearable Injectors Market for Digestive Disorders (Number of Devices, Millions), 2014 - 2025
Figure 8.19 Number of Molecules in Large Volume Wearable Injectors for Musculoskeletal Disorders (2014 - 2025)
Figure 8.20 Large Volume Wearable Injectors Market for Musculoskeletal Disorders (Number of Devices, Millions), 2014 - 2025
Figure 8.21 Number of Molecules in Large Volume Wearable Injectors for Diabetes (2014 - 2025)
Figure 8.22 Large Volume Wearable Injectors Market for Diabetes (Number of Devices, Millions), 2014 - 2025
Figure 8.23 Number of Molecules in Large Volume Wearable Injectors for Eye Conditions (2014 - 2025)
Figure 8.24 Large Volume Wearable Injectors Market for Eye Conditions (Number of Devices, Millions), 2014 - 2025
Figure 8.25 Number of Molecules in Large Volume Wearable Injectors for Skin Diseases (2014 - 2025)
Figure 8.26 Large Volume Wearable Injectors Market for Skin Diseases (Number of Devices, Millions), 2014 - 2025
Figure 8.27 Number of Molecules in Large Volume Wearable Injectors for Neurologic Disorders (2014 - 2025)
Figure 8.28 Large Volume Wearable Injectors Market for Neurologic Disorders (Number of Devices, Millions), 2014 - 2025
Figure 8.29 Number of Molecules in Large Volume Wearable Injectors for Other Diseases (2014 - 2025)
Figure 8.30 Large Volume Wearable Injectors Market for Other Diseases (Number of Devices, Millions), 2014 - 2025
Figure 9.1 Number of Biologics Approved by the US FDA, 2009-2013
Figure 9.2 Remodulin Sales by United Therapeutics, 2007-2013 (USD Million)
Figure 9.3 Tyvaso Sales by United Therapeutics, 2009-2013 (USD Million)
Figure 10.1 Revenues, Unilife Corporation, FY 2011 - FY 2013 (USD ‘000)
Figure 10.2 West Pharmaceutical Services, 2011-2013, Sales by Business Divisions (USD Million, %)
Figure 10.3 BD Medical, 2011-2013- Sales by Business Divisions (USD Billion, %)
Figure 10.4 Roche Annual Sales, 2009-2013 (CHF Million)
Figure 10.5 Roche Annual Sales, 2013: Distribution by Business Segment (CHF Million)
Figure 10.6 Roche Pharmaceuticals Annual Sales, 2013: Distribution by Segment (%)
Figure 12.1 Large Volume Wearable Injectors Market (Number of Devices, Millions): 2016, 2020, 2025
Figure 12.2 Large Volume Wearable Injectors Market (USD Million): 2016, 2020, 2025

List of Tables

Table 4.1 Traditional Pump Devices vs. Large Volume Wearable Injectors
Table 4.2 Large Volume Wearable Injectors: Benefits v/s Perceived Issues
Table 4.3 Large Volume Wearable Injectors Under Development
Table 5.1 Biologics Under Consideration for Large Volume Wearable Injectors: Most Likely Candidates
Table 5.2 Biologics Under Consideration for Large Volume Wearable Injectors: Likely Candidates
Table 5.3 Biologics Under Consideration for Large Volume Wearable Injectors: Less Likely Candidates
Table 5.4 Biologics Under Consideration for Large Volume Wearable Injectors: Other  Candidates
Table 6.1 Drugs Under Development for Delivery Through Large Volume Wearable Injectors
Table 6.2 Furosemide Manufacturers, 2014
Table 6.3 Cephalosporin Classification by Generation
Table 6.4 Evolocumab: Completed Phase III Studies
Table 6.5 Evolocumab: Some Ongoing Clinical Trials
Table 6.6 List of Some Manufacturers of Levodopa/Carbidopa Fixed Combinations
Table 7.1 Clinical Trials Evaluating MyDose
Table 9.1 SWOT Analysis of the Large volume wearable Injectors Market
Table 9.2 List of Available Autoinjectors, 2013
Table 9.3 Recall of Autoinjectors
Table 9.4 Prefilled Syringe Recalls, 2003-2014
Table 13.1 Prevalence of Diabetes, 2013 - By Countries (Million, %)
Table 13.2 Large Volume Wearable Injectors: Distribution by Modes of Operation
Table 13.3 Large Volume Wearable Injectors: Distribution by Device Usage
Table 13.4 Large Volume Wearable Injectors: Distribution by Volume
Table 13.5 Total Drugs Market, 2013: Distribution by Nature of Drug (USD Billion, %)
Table 13.6 Total Drugs Market Forecast, (2014-2020): Distribution by Biologics and Pharmaceuticals (USD Billion)
Table 13.7 Biologic Drugs in Development: Distribution by Type of Molecule (%)
Table 13.8 Overall Large Volume Wearable Injectors Market (Number of Devices, Million), 2014 – 2025 – Base Scenario
Table 13.9 Overall Large Volume Wearable Injectors Market (USD Million), 2014 – 2025– Base Scenario
Table 13.10 Number of Molecules in Large Volume Wearable Injectors for Cancer and Related Conditions, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.11 Large Volume Wearable Injectors Market for Cancer and Related Conditions (Number of Devices, Million), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.12 Number of Molecules in Large Volume Wearable Injectors for Autoimmune Diseases, 2014 -2025 (Conservative, Base, Optimistic Scenarios)
Table 13.13 Large Volume Wearable Injectors Market for Autoimmune Diseases (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.14 Number of Molecules in Large Volume Wearable Injectors for Blood Disorders, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.15 Large Volume Wearable Injectors Market for Blood Disorders (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.16 Number of Molecules in Large Volume Wearable Injectors for Genetic Disorders, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.17 Large Volume Wearable Injectors Market for Genetic Disorders (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.18 Number of Molecules in Large Volume Wearable Injectors for Infectious Diseases, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.19 Large Volume Wearable Injectors Market for Infectious Diseases (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.20 Number of Molecules in Large Volume Wearable Injectors for Cardiovascular Diseases, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.21 Large Volume Wearable Injectors Market for Cardiovascular Diseases (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.22 Number of Molecules in Large Volume Wearable Injectors for Respiratory Disorders, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.23 Large Volume Wearable Injectors Market for Respiratory Disorders (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.24 Number of Molecules in Large Volume Wearable Injectors for Digestive Disorders, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.25 Large Volume Wearable Injectors Market for Digestive Disorders (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.26 Number of Molecules in Large Volume Wearable Injectors for Musculoskeletal Disorders, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.27 Large Volume Wearable Injectors Market for Musculoskeletal Disorders (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.28 Number of Molecules in Large Volume Wearable Injectors for Diabetes, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.29 Large Volume Wearable Injectors Market for Diabetes (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.30 Number of Molecules in Large Volume Wearable Injectors for Eye Conditions, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.31 Large Volume Wearable Injectors Market for Eye Conditions (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.32 Number of Molecules in Large Volume Wearable Injectors for Skin Diseases, 2014 -2025 (Conservative, Base, Optimistic Scenarios)
Table 13.33 Large Volume Wearable Injectors Market for Skin Diseases (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.34 Number of Molecules in Large Volume Wearable Injectors for Neurologic Disorders, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.35 Large Volume Wearable Injectors Market for Neurologic Disorders (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.36 Number of Molecules in Large Volume Wearable Injectors for Other Diseases, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
Table 13.37 Large Volume Wearable Injectors Market for Other Diseases (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)

Listed Companies

The following companies have been mentioned in this report.

  1. Abbott Laboratories
  2. AbbVie
  3. AbGenomics
  4. Abingworth
  5. Accord Healthcare
  6. Acorda Therapeutics
  7. Actinium Pharmaceuticals
  8. Adaptimmune
  9. Aduro Biotech
  10. Advanced Technology Ventures
  11. Agate Medical Investments
  12. Agensys
  13. Alder Biopharmaceuticals
  14. Alexion Pharmaceuticals
  15. Alnylam Pharmaceuticals
  16. Altor Bioscience
  17. Alverix Inc.
  18. AM2PAT Inc. 
  19. Ambimed
  20. Amgen
  21. Antaric Pharma
  22. Apotex
  23. Aramon Neuromedical
  24. Ascletis Bioscience
  25. Aspen Pharmacare
  26. Astellas Pharma
  27. Astra Zeneca
  28. Athersys
  29. Auda Private Equity
  30. Aurum Pharmceuticals
  31. AVEO Oncology
  32. Bang & Olufsen
  33. Battelle
  34. Baxter International
  35. Bayer
  36. Becton Dickinson
  37. Bespak
  38. BioArctic Neuroscience
  39. Biodel
  40. Biogen Idec
  41. BioInvent International
  42. BioMarin Pharmaceutical
  43. Bluebird bio
  44. BMS
  45. Boehringer Ingelheim
  46. Bracco Diagnostics
  47. Calibra Medical
  48. Catalyst Biosciences
  49. Cato Software Solutions
  50. Celgene Cellular Therapeutics
  51. Cell Medica
  52. Celldex Therapeutics
  53. Cellerant Therapeutics
  54. Centocor Ortho Biotech, Inc.
  55. Central Illinois Angels
  56. CeQur SA
  57. Children's Hospital Boston
  58. CHL Medical Partners
  59. Ciradian Technologies
  60. Constitution Medical Investors
  61. Covidien
  62. CSL Behring
  63. Cure Tech
  64. Cytomedix
  65. Cytonet
  66. Daiichi Sankyo
  67. Daikyo Seiko Ltd
  68. Danfoss A/S
  69. Dekkun
  70. Denderon
  71. Eisai
  72. Elan Pharmaceuticals
  73. Elcam Medical
  74. Eli Lilly
  75. Elusys Therapeutics
  76. Emergent Biosolutions
  77. Enable Injections
  78. Enbrel
  79. Excellium
  80. Excelsior Medical
  81. FibroGen
  82. Five Prime Therapeutics
  83. Flugen 
  84. Future Injection Technologies
  85. Genentech
  86. Genethon
  87. Genia Technologies
  88. Geno Pharmaceuticals
  89. Genzyme
  90. Gilead Sciences
  91. GSK
  92. GTC Biotherapeutics
  93. Halozyme Therapeutics
  94. Haselmeier
  95. Healthcare Pharmaceuticals(formerly Dekkun)
  96. Hemispherx Biopharma
  97. Hikma
  98. HLM Venture Partners
  99. Hospira
  100. ImClone Systems
  101. Immunomedics
  102. Immunovative Therapies
  103. InnoKeys PTE
  104. INSERM
  105. Insulet
  106. Ipca Laborataries
  107. IQuum 
  108. Isis Pharmaceuticals
  109. J&J
  110. Janssen Biologics
  111. Janssen Biotech
  112. Kaiser Permanente Ventures
  113. KaloBios Pharmaceuticals
  114. KB Partners
  115. Kyowa Hakko Kirin
  116. Lincoln Medical Limited
  117. MacroGenics
  118. MassBiologics
  119. MedImmune
  120. Medingo
  121. Medipac
  122. Merck
  123. Meridian Medical Technologies
  124. Merrimack Pharmaceuticals
  125. Milennium Pharmaceuticals
  126. Molmed
  127. MorphoSys
  128. Mpax Phamaceuticals
  129. MPM Capital
  130. Mylan Pharmaceuticals
  131. NeuroDerm
  132. Norwich Pharmaceuticals
  133. Nourish Pharmaceutical
  134. Novartis
  135. Novo Nordisk
  136. Nuron Biotech
  137. Octapharma
  138. OncoGenex Technologies
  139. OncoMed
  140. ONSET Ventures
  141. Osiris Therapeutics
  142. Owen Mumford
  143. Peregrine Pharmaceuticals
  144. Pfizer
  145. PhaseBio Pharmaceuticals
  146. Pitango Venture Capital
  147. Pluristem Therapeutics
  148. Polyphor
  149. Prachi Pharmaceuticals
  150. Prometheus Laboratories
  151. Protalix Biotherapeutics
  152. Prothena Corporation
  153. Quintessensce Biosciences
  154. Qualitest Pharmaceuticals
  155. Ranbaxy Pharmaceuticals
  156. Ratio, Inc.
  157. rEVO Biologics (formerly GTC Biotherapeutics)
  158. Roche
  159. Roxane Laboratories
  160. Samson Ventures
  161. Sandoz
  162. Sangamo BioSciences
  163. Sanofi Aventis
  164. Sanofi Oncology
  165. Sanofi Pasteur
  166. Sarpeta Therapeutics
  167. Sartorius Stedim Biotech
  168. Savient Pharmaceuticals
  169. Schwarz Pharma
  170. Sciele Pharma, Inc.
  171. ScPharmaceuticals
  172. Seattle Genetics
  173. Seattle Medical Technologies
  174. Selexys Pharmaceuticals
  175. Senesco Technologies
  176. Sensile Medical
  177. Seragon Pharmaceuticals
  178. Shiongi Pharma, Inc.
  179. Shire
  180. SHL Medical
  181. Sillajen Biotherapeutics
  182. Spectrum Pharmaceuticals
  183. Stateline Angels
  184. SteadyMed Therapeutics
  185. Sun Pharmaceuticals
  186. Synageva BioPharma
  187. TaiMed Biologics
  188. Takeda Pharmaceuticals
  189. Tekmira Pharmaceuticals
  190. Teva Pharmaceuticals
  191. TG Therapeutics
  192. The Golden Angels Network
  193. Theraclone Sciences
  194. TRACON Pharmaceuticals
  195. Tullis Health Investors
  196. UCB
  197. Unilife
  198. United Biomedical
  199. United Therapeutics
  200. Vaccinex
  201. Valeritas
  202. VBL Therapeutics
  203. Vintage Pharmaceuticals
  204. Welsh, Carson, Anderson & Stowe
  205. West Pharmaceutical Services
  206. Wisconsin Investment Partners
  207. Xbiotech
  208. Xencor
  209. Ypsomed
  210. ZZ Biotech

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 1,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com